Company profile
KURA ONCOLOGY, INC.
NASDAQ:KURABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| KOMZIFTI | approved | $9.1MQ2 2026 | 5 | approved |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06655246 | phase1 | recruiting | 2025-03-27 | 2027-12-01 | Kura Oncology, Inc. | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) |
| NCT05735184 | phase1 | recruiting | 2023-07-18 | 2030-04-01 | Kura Oncology, Inc. | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML |
| NCT04865159 | phase1 | terminated | 2021-05-06 | 2023-05-02 | Kura Oncology, Inc. | Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies |
| NCT04997902 | phase1_2 | completed | 2021-12-07 | 2025-08-29 | Kura Oncology, Inc. | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) |
| NCT04067336 | phase1_2 | active_not_recruiting | 2019-09-12 | 2028-10-16 | Kura Oncology, Inc. | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 220305 | 2025-11-13 | NDA | KURA ONCOLOGY INC | |||||
Loading… | ||||||||